WIA
SAGE

Wealthstreet Investment Advisors’s Sage Therapeutics SAGE Stock Holding History

Wealthstreet Investment Advisors’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,300
Closed -$207K – 349
2019
Q1 		$207K Buy
+1,300
New +$188K 0.03% 323

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Wealthstreet Investment Advisors's SAGE Position: Q2 2019 in Review

Wealthstreet Investment Advisors sold out of Sage Therapeutics (SAGE) in Q2 2019, closing a stake of 1,300 shares — an estimated $207K sold.

Wealthstreet Investment Advisors first reported a position in SAGE in Q1 2019 and held it in 1 quarter. The position peaked at $207K in Q1 2019. 272 funds tracked by Wall St. Rank hold SAGE as of Q2 2019.

  • Wealthstreet Investment Advisors reported no remaining Sage Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Wealthstreet Investment Advisors sold 1,300 Sage Therapeutics shares in Q2 2019, an estimated $207K.
  • Wealthstreet Investment Advisors first reported a position in Sage Therapeutics in Q1 2019 and held it in 1 quarter.
  • Wealthstreet Investment Advisors's Sage Therapeutics position peaked at $207K in Q1 2019.
  • 272 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2019.

Based on Wealthstreet Investment Advisors's 13F filing for Q2 2019, filed 16 Jul 2019.